Your browser doesn't support javascript.
loading
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.
Advani, Anjali S; Tse, William; Li, Hong; Jia, Xuefei; Elson, Paul; Cooper, Brenda; Ali-Osman, Francis; Park, Jino; Rao, Arati V; Rizzieri, David A; Wang, Eunice S; Cotta, Claudiu V; Kalaycio, Matt; Sobecks, Ronald M; Rouphail, Basel; Maciejewski, Jaroslaw P; Fensterl, Jaime; Carew, Jennifer S; Foster, Bethany; Rush, Mary Lynn; Tripp, Barbara; Adams, Donna; Corrigan, Donna; Griffiths, Elizabeth A; Sekeres, Mikkael A.
Afiliación
  • Advani AS; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH. Electronic address: advania@ccf.org.
  • Tse W; Department of Hematology/ Oncology, Metro Health, Cleveland, OH.
  • Li H; Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH.
  • Jia X; Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH.
  • Elson P; Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH.
  • Cooper B; Department of Hematology/ Oncology, University Hospitals of Cleveland, Cleveland, OH.
  • Ali-Osman F; Department of Hematology/ Oncology, Duke University, Durham, NC.
  • Park J; James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY.
  • Rao AV; Duke Cancer Institute, Duke University, Durham, NC; Current affiliation: PACT Pharma, South San Francisco, CA.
  • Rizzieri DA; Duke Cancer Institute, Duke University, Durham, NC.
  • Wang ES; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
  • Cotta CV; Department of Pathology, Cleveland Clinic, Cleveland, OH.
  • Kalaycio M; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Sobecks RM; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Rouphail B; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Maciejewski JP; Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Fensterl J; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Carew JS; University of Arizona Cancer Center, Leon Levy Cancer Center, Tuscon, AZ.
  • Foster B; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Rush ML; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Tripp B; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Adams D; Department of Hematology/ Oncology, Duke University, Durham, NC.
  • Corrigan D; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
  • Griffiths EA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
  • Sekeres MA; Department of Hematology/ Oncology, Cleveland Clinic Taussig Cancer Institute Leukemia Program, Cleveland, OH.
Clin Lymphoma Myeloma Leuk ; 21(2): 113-118, 2021 02.
Article en En | MEDLINE | ID: mdl-33422470
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Proteínas Proto-Oncogénicas c-kit / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Proteínas Proto-Oncogénicas c-kit / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Recurrencia Local de Neoplasia Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article